Business

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win

articleBridgebio Pharma, Inc.December 5, 20234/company/bridgebio-pharma-inc/news/bridgebio-pharma-announces-submission-of-new-drug-application-nda-to-us-food-and

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

About this update from Bridgebio Pharma, Inc.

[{"type":"text","content":"- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p","length":222,"tagName":"div"}]

More updates from Bridgebio Pharma, Inc.